BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.
FDA Advisory Committee Recommends Use Maribavir to Treat Post-Transplant Recipients with CMV Infection and Disease Refractory to Treatment With or Without Resistance
Adults, Advisory Panels, Antimicrobial Drugs Advisory Committee, Clinical Trials, Cytomegalovirus Infections, Organ Transplantation, R&D, Recommended For Approval, TakedaThe U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of Takeda Pharmaceutical Company Limited’s maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease withgenotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.
Merck & Co.’s experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in late-stage trial.